(Q55981202)

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Alpha emitter radium-223 and survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Overcoming mutation-based resistance to antiandrogens with rational drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

The mutational landscape of lethal castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Therapeutic targeting of the prostate cancer microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

ARN-509: a novel antiandrogen for prostate cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

An androgen receptor N-terminal domain antagonist for treating prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Immunotherapy for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Efficacy of c-Met inhibitor for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Improved endpoints for cancer immunotherapy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU038